Track market-moving stories before they get noisy

On July 22, 2026, Privia Health Group Inc (PRVA) shares fell 3.6% today, bringing the current price to $25.37. Over the past 52 weeks, the stock has fluctuated

ARLINGTON, Va., July 07, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced that it expects to release financial results for its second-quarter and six-month periods ended June 30, 2026 before market open on Thursday, August 6, 2026.

The press release is expected to be publicly disseminated by 7:00 am ET and will also be available on the Company’s Investor Relations website at ir.priviahealth.com. Privia Health management will host a conference call beginning at 8:00 am ET on the same day, Thursday, August 6, to discuss the results and management’s outlook for future financial and operational performance.

You can visit ir.priviahealth.com/news-and-events/events-and-presentations to listen to the call via live webcast. The webcast will be archived and available for replay for on-demand listening shortly after the completion of the call under the same link. Go to https://register-conf.media-server.com/register/BI4c0355cb60f4473db6a27e261c9996e2 to pre-register and obtain your dial-in number and passcode to join the live conference call.

About Privia Health

Privia Health™ is one of the largest physician enablement companies in the United States with a presence in 25 states and the District of Columbia. Privia builds scaled provider networks with primary-care centric medical groups, risk-bearing entities, a physician-led governance structure, and the Privia Platform comprising an extensive suite of technology and service solutions. Privia collaborates with medical groups, health plans and health systems to optimize 1,300+ physician practices, improve the patient experience for 5.9+ million patients, and reward 5,500+ physicians and advanced practitioners for delivering high-value care.

Privia’s mission is to transform healthcare delivery to achieve better outcomes, lower costs, and improve the health of communities and the well-being of providers. For more information, visit priviahealth.com.

Contact
Robert Borchert
SVP, Investor & Corporate Communications
[email protected] 
817.783.4841

David Mountcastle, EVP & Chief Financial Officer of Privia Health Group (PRVA +0.58%), reported the direct sale of 13,018 shares over March 12 and March 13, 2026, for a total transaction value of approximately $283,000 according to a SEC Form 4 filing.

Transaction summaryMetricValueShares sold (direct)13,018Transaction value$283,000Post-transaction shares (direct)226,804Post-transaction shares (indirect)8,695Post-transaction value (direct ownership)~$4.92 millionTransaction value based on SEC Form 4 weighted average purchase price ($21.71); post-transaction value based on March 13, 2026 market close ($21.68).

Key questionsWhat was the impact on Mountcastle’s ownership percentage and remaining share capacity?
The transaction reduced his direct holdings by 5.24%, leaving Mountcastle with 226,804 directly held shares and a remaining direct ownership stake of 0.18% of the company’s outstanding shares as of the filing.Were there any indirect or derivative mechanics involved in this transaction?
No indirect or derivative securities were involved; the transaction consisted entirely of direct open-market sales, with indirect holdings (8,695 shares via spouse) unchanged by this filing.Company overviewMetricValueMarket capitalization$2.61 billionRevenue (TTM)$2.12 billionNet income (TTM)$22.92 million1-year price change (as of 3/21/26)-10.15%

Today's Change

(

0.58

%) $

0.14

Current Price

$

23.50

Company snapshotPrivia Health Group operates as a national physician-enablement company, supporting over 1,100 employees and a broad network of providers. It offers technology platforms, population health tools, and management services to optimize physician practices and reduce the administrative burdens of independent physicians.

What this transaction means for investorsThis sale of shares by Mountcastle was strictly for tax withholding obligations tied to the vesting of performance stock units, so investors shouldn’t let this transaction affect their investing decisions on PRVA stock. In a previous filing, the CFO had 35,335 restricted stock units vest on March 10, while 42,584 performance stock units vested the next day. So a sale to cover taxes was likely imminent. The EVP even sold 6,391 more shares on the 16th, at $22.11 per share, for a total of $141,241, which was also to cover taxes.

While PRVA share prices are down 10% in 2026, the company’s financials were fairly strong in its Q4 FY 2025 earnings report in late February. Privia exceeded earnings expectations, posting 7 cents per share for the quarter, above the 4-cent estimate and the highest year-over-year (YoY) growth since Q3 2023. 

Privia is still looking to grow its value-based operations, as it’s highly optimistic about its acquisition of Accountable Care Organization (ACO) back in late September 2025. With the purchase, Privia gained approximately 1.5 million customers who possess medical plans such as Medicare, Medicare Advantage, and Medicaid.

Adé Hennis has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Posted by Defense World Staff on Apr 4th, 2026

JPMorgan Chase & Co. increased its holdings in Privia Health Group, Inc. (NASDAQ:PRVA – Free Report) by 26.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 148,709 shares of the company’s stock after acquiring an additional 30,845 shares during the quarter. JPMorgan Chase & Co. owned about 0.12% of Privia Health Group worth $3,703,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also made changes to their positions in PRVA. Royal Bank of Canada grew its stake in shares of Privia Health Group by 63.5% in the 1st quarter. Royal Bank of Canada now owns 245,633 shares of the company’s stock worth $5,514,000 after buying an additional 95,371 shares during the last quarter. AQR Capital Management LLC grew its stake in shares of Privia Health Group by 24.7% in the first quarter. AQR Capital Management LLC now owns 40,781 shares of the company’s stock worth $916,000 after acquiring an additional 8,068 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Privia Health Group by 3.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 118,764 shares of the company’s stock valued at $2,666,000 after acquiring an additional 3,714 shares in the last quarter. Intech Investment Management LLC raised its position in shares of Privia Health Group by 55.1% in the 1st quarter. Intech Investment Management LLC now owns 56,553 shares of the company’s stock worth $1,270,000 after purchasing an additional 20,082 shares during the last quarter. Finally, Acadian Asset Management LLC bought a new position in Privia Health Group in the 1st quarter worth about $154,000. Institutional investors own 94.48% of the company’s stock.

Wall Street Analysts Forecast Growth Several research analysts have issued reports on the stock. Barclays lifted their target price on shares of Privia Health Group from $23.00 to $25.00 and gave the stock an “equal weight” rating in a report on Wednesday, March 25th. Piper Sandler reiterated an “overweight” rating and set a $36.00 target price on shares of Privia Health Group in a research note on Thursday, February 26th. Citigroup decreased their price target on Privia Health Group from $34.00 to $32.00 and set a “buy” rating for the company in a research note on Tuesday, March 3rd. Wolfe Research set a $31.00 price objective on Privia Health Group in a research report on Tuesday, January 6th. Finally, Canaccord Genuity Group boosted their target price on Privia Health Group from $34.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Thirteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $31.13.

Check Out Our Latest Research Report on PRVA

Insider Buying and Selling at Privia Health Group In related news, CEO Parth Mehrotra sold 26,509 shares of Privia Health Group stock in a transaction on Monday, March 16th. The stock was sold at an average price of $22.11, for a total transaction of $586,113.99. Following the transaction, the chief executive officer directly owned 555,443 shares in the company, valued at approximately $12,280,844.73. The trade was a 4.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO David Mountcastle sold 6,391 shares of the firm’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $22.11, for a total value of $141,305.01. Following the completion of the transaction, the chief financial officer directly owned 220,413 shares in the company, valued at $4,873,331.43. This trade represents a 2.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 242,191 shares of company stock valued at $5,520,587. Insiders own 10.70% of the company’s stock.

Privia Health Group Price Performance NASDAQ PRVA opened at $21.21 on Friday. The stock has a market capitalization of $2.62 billion, a price-to-earnings ratio of 124.76, a PEG ratio of 1.32 and a beta of 0.87. Privia Health Group, Inc. has a 1-year low of $18.77 and a 1-year high of $26.51. The business’s fifty day moving average price is $22.14 and its 200-day moving average price is $23.41.

Privia Health Group (NASDAQ:PRVA – Get Free Report) last posted its quarterly earnings data on Thursday, February 26th. The company reported $0.25 EPS for the quarter, beating analysts’ consensus estimates of $0.04 by $0.21. The company had revenue of $541.17 million during the quarter, compared to analysts’ expectations of $516.61 million. Privia Health Group had a return on equity of 3.06% and a net margin of 1.08%.Privia Health Group’s revenue for the quarter was up 17.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.21 earnings per share. Equities research analysts anticipate that Privia Health Group, Inc. will post 0.14 EPS for the current year.

Privia Health Group Profile (Free Report)

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.

See Also Five stocks we like better than Privia Health Group

Receive News & Ratings for Privia Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Privia Health Group and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINESG Americas Securities LLC Raises Stock Holdings in Webull Corporation $BULL

NEXT HEADLINE »JPMorgan Chase & Co. Acquires 107,010 Shares of iShares iBonds Dec 2029 Term Corporate ETF $IBDU

Strong First Quarter Performance and Operating ExecutionReiterated Full-Year 2026 Guidance Reflects Continued Momentum ARLINGTON, Va., May 07, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced financial results for the first quarter ended March 31, 2026.

  Three Months Ended March 31,  (unaudited; $ in millions, except per share amounts) 2026 2025 Change (%)*       Total revenue $603.8 $480.1 25.8%Gross profit $125.6 $103.6 21.2%Operating income $7.4 $5.2 42.2%Net income a $3.1 $4.2 (27.4)%Non-GAAP adjusted net income b $24.3 $19.9 22.3%Net income per share $0.02 $0.03 (33.3)%Non-GAAP adjusted net income per share b $0.19 $0.16 18.8%        * Any slight variations in totals are due to rounding.

a. Net income for the three months ended March 31, 2026, included $21.9 million in non-cash stock compensation expense. Net income for the three months ended March 31, 2025 included $17.8 million in non-cash stock compensation expense.

b. Reconciliations of non-GAAP adjusted net income and other non-GAAP financial measures are presented in tables near the end of this press release.

First Quarter 2026 highlights include:

Continued strength in same-store growth and new provider additions;Practice Collections of $914.8M, +14.6% versus 1Q’25; andAdjusted EBITDA c e f of $36.7M, +36.3% versus 1Q’25.
Key Operating and Non-GAAP Financial Metrics c

  Three Months Ended March 31,  (unaudited; $ in millions) 2026 2025 Change (%)       Implemented Providers  5,535  4,871 13.6%Value-Based Care Attributed Lives  1,606,000  1,270,000 26.5%Practice Collections $914.8 $798.6 14.6%Care Margin $128.7 $105.3 22.3%Platform Contribution $67.0 $51.7 29.6%Adjusted EBITDA $36.7 $26.9 36.3%        c. Reconciliations of Care Margin, Platform Contribution, Adjusted EBITDA and other non-GAAP financial measures are presented in tables near the end of this press release.

Updated Full-Year 2026 Guidance d e f g

Privia Health maintained its full-year 2026 outlook for most metrics, and raised its guidance range for Attributed Lives, as follows:

 FY 2025 Initial FY 2026 Guidance at 2.27.26d Updated FY 2026 Guidance
at 5.7.26($ in millions)Actual Low High  Implemented Providers 5,380  5,900  6,000 UnchangedAttributed Lives 1,541,000  1,550,000  1,600,000 1,600,000 - 1,625,000Practice Collections$3,470.5 $3,650 $3,750 UnchangedGAAP Revenue$2,122.8 $2,350 $2,450 UnchangedCare Margin d e f$462.2 $515 $530 UnchangedPlatform Contribution d e$234.8 $260 $270 UnchangedAdjusted EBITDA d e f$125.5 $145 $155 Unchanged            Expect approximately 80% of Adjusted EBITDA to convert to free cash flow in full-year 2026Guidance does not assume any new business development activity d. Management has not reconciled forward-looking non-GAAP measures to their most directly comparable GAAP measures of Gross Profit, Operating Income and Net Income. This is because the Company cannot predict with reasonable certainty and without unreasonable efforts the ultimate outcome of certain GAAP components of such reconciliations due to market-related assumptions that are not within our control as well as certain legal or advisory costs, tax costs or other costs that may arise. For these reasons, management is unable to assess the probable significance of the unavailable information, which could materially impact the amount of the future directly comparable GAAP measures.

e. See “Key Metrics and Non-GAAP Financial Measures” for more information as to how the Company defines and calculates Implemented Providers, Attributed Lives, Practice Collections, Care Margin, Platform Contribution, and Adjusted EBITDA, and for a reconciliation of the most comparable GAAP measures to Care Margin, Platform Contribution, Adjusted EBITDA, Adjusted Net Income and Adjusted Net Income Per Share.

f. Certain non-recurring or non-cash and other expenses will be treated as an add back in the reconciliation of Net Income to Adjusted EBITDA, and the reconciliation of Net Income to Adjusted Net Income and Adjusted Net Income Per Share, the details of which can be found in the Reconciliation schedules near the end of this and in future quarterly press releases.

g. Any slight variations in totals due to rounding.

Webcast and Conference Call Information

The Company will host a conference call on May 7, 2026, at 8:00 am ET to discuss these results and management’s outlook for future financial and operational performance. You can visit ir.priviahealth.com/news-and-events/events-and-presentations to listen to the call via live webcast. The webcast will be archived and available for replay for on-demand listening shortly after the completion of the call under the same link. If you wish to participate in the live conference call, then please dial 888-596-4144 (or 646-968-2525 for international callers) and provide Conference ID 5704885.

This news release and the financial statements contained herein, and the slide presentation for the webcast, are also available on the Privia Health Investor Relations website at ir.priviahealth.com.

About Privia Health

Privia Health™ is one of the largest physician enablement companies in the United States with a presence in 24 states and the District of Columbia. Privia builds scaled provider networks with primary-care centric medical groups, risk-bearing entities, a physician-led governance structure, and the Privia Platform comprising an extensive suite of technology and service solutions. Privia collaborates with medical groups, health plans and health systems to optimize 1,300+ physician practices, improve the patient experience for 5.9+ million patients, and reward 5,500+ physicians and advanced practitioners for delivering high-value care.

Privia’s mission is to transform healthcare delivery to achieve better outcomes, lower costs, and improve the health of communities and the well-being of providers. For more information, visit priviahealth.com.

Non-GAAP Financial Measures

The Company reports and discusses its operating results using financial measures consistent with accounting principles generally accepted in the United States ("GAAP"). From time to time, in press releases, financial presentations, earnings conference calls or otherwise, the Company may disclose certain non-GAAP financial measures. The non-GAAP financial measures presented in this press release should not be viewed as alternatives or substitutes for the Company's reported GAAP results. A reconciliation to the most directly comparable GAAP financial measure is set forth in the tables that accompany this release.

The Company believes that the non-GAAP financial measures presented in this press release are relevant and provide useful information to the Company's management, investors, and other interested parties about the Company's operating performance because the measures allow them to understand and compare the Company's actual and expected operating results during the prior, current and future periods in a more consistent manner. The non-GAAP measures presented in this press release may not be comparable to similarly titled measures used by other companies. These non-GAAP financial measures are used in addition to and in conjunction with results presented in accordance with GAAP and reflect an additional way of viewing aspects of the Company's operations that, when viewed with GAAP results and the accompanying reconciliations to corresponding GAAP financial measures, provides a more complete understanding of the results of operations and trends affecting the Company's business. These non-GAAP financial measures should be considered as a supplement to, and not as a substitute for, or superior to financial measures calculated in accordance with GAAP.

Safe Harbor Statement

The financial results in this press release reflect preliminary, unaudited results, which are not final until the Company’s Form 10-Q is filed with the Securities and Exchange Commission (“SEC”). This press release contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such statements relate to our current expectations, projections and assumptions about our business, the economy and future events or conditions. They do not relate strictly to historical or current facts. Forward-looking statements can be identified by words such as “aims,” “anticipates,” "assumes," “believes,” “estimates,” “expects,” “forecasts,” “future,” “intends,” “likely,” “may,” “outlook,” “plans,” “potential,” “projects,” “seeks,” “strategy,” “targets,” “trends,” “will,” “would,” “could,” “should,” and variations of such terms and similar expressions and references to guidance, although some forward-looking statements may be expressed differently. In particular, these include statements relating to, among other things, our future actions, business plans, objectives and prospects; and our future operating or financial performance and projections, including our full year guidance for 2026. Factors or events that could cause actual results to differ may emerge from time to time and are difficult to predict. Should known or unknown risks or uncertainties materialize, or should underlying assumptions prove inaccurate, actual results may differ materially from past results and those anticipated, estimated or projected. We caution you not to place undue reliance upon any of these forward-looking statements.

Factors related to these risks and uncertainties include, but are not limited to: the heavily regulated industry in which we operate, and any failure by us or our medical groups to comply with the extensive applicable healthcare laws and government regulations; the complexity of the legal framework governing our relationships with Medical Groups, some of which we do not own, and Privia providers, and the impact of legal challenges or shifting interpretations of applicable laws; the execution of our growth strategy, which may not prove viable and we may not realize expected results; difficulties timely implementing our proprietary end-to-end, cloud-based technology solution for Privia physicians and new medical groups; the high level of competition in our industry; challenges in successfully establishing a presence in new geographic markets; the impact of failures by or service disruptions at key third-party vendors, such as our primary electronic medical record vendor, athenahealth, Inc.; potential decreases in reimbursement rates by governmental and third-party payers, changes to payment terms or challenges negotiating and retaining favorable contracts with private third-party payers, and changes impacting our patient population; the financial and operational impact of our compliance with various complex and changing federal and state privacy and security laws and regulations related to our use, disclosure, and other processing of personal information and protected health information, including the Health Insurance Portability and Accountability Act of 1996; the impact of actual and potential security threats, cybersecurity incidents or privacy or other forms of data breaches involving us, our vendors or other third parties; the continued availability of qualified workforce, including staff at our medical groups, and the continued upward pressure on compensation for such workforce; and other risk factors described in our Annual Report on Form 10-K for the year ended December 31, 2025 and the Company’s subsequent Quarterly Reports on Form 10-Q. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.

Contact:
Robert Borchert
SVP, Investor & Corporate Communications
[email protected]
817.783.4841

   Privia Health Group, Inc.
Condensed Consolidated Statements of Operations(g)
(unaudited)
(in thousands, except share and per share data)
    For the Three Months Ended March 31,
 2026
 2025
      Revenue$603,847  $480,097       Operating expenses:     Provider expense 475,117   374,809 Cost of platform 68,420   59,526 Sales and marketing 8,134   6,922 General and administrative 41,473   31,721 Depreciation and amortization 3,281   1,901 Total operating expenses 596,425   474,879 Operating income 7,422   5,218 Interest income, net 1,888   2,931 Income before provision for income taxes 9,310   8,149 Provision for income taxes 5,600   2,103 Net income 3,710   6,046 Less: Net income attributable to non-controlling interests 646   1,826 Net income attributable to Privia Health Group, Inc.$3,064  $4,220 Net income per share attributable to Privia Health Group, Inc. stockholders – basic$0.02  $0.03 Net income per share attributable to Privia Health Group, Inc. stockholders – diluted$0.02  $0.03 Weighted average common shares outstanding – basic 124,152,526   120,623,670 Weighted average common shares outstanding – diluted 130,878,939   127,752,527          (g) Any slight variations in totals due to rounding.

Privia Health Group, Inc.
Condensed Consolidated Balance Sheets(h)
(in thousands)
     March 31, 2026 December 31, 2025Assets(unaudited)  Current assets:   Cash and cash equivalents$419,524  $479,685 Accounts receivable 513,676   400,902 Prepaid expenses and other current assets 32,822   30,414 Total current assets 966,022   911,001 Non-current assets:   Property and equipment, net 384   504 Right-of-use assets 8,307   8,794 Intangible assets, net 212,784   215,919 Goodwill 209,842   209,842 Deferred tax asset —   2,274 Other non-current assets 20,553   21,044 Total non-current assets 451,870   458,377 Total assets$1,417,892  $1,369,378     Liabilities and stockholders’ equity   Current liabilities:   Accounts payable and accrued expenses$80,555  $96,804 Provider liability 518,629   469,516 Operating lease liabilities, current 2,114   2,200 Total current liabilities 601,298   568,520 Non-current liabilities:   Operating lease liabilities, non-current 6,907   7,331 Deferred tax liability 254   — Other non-current liabilities 3,529   2,584 Total non-current liabilities 10,690   9,915 Total liabilities 611,988   578,435 Commitments and contingencies   Stockholders’ equity:   Common stock 1,257   1,236 Additional paid-in capital 905,048   892,291 Accumulated deficit (153,246)  (156,310)Total Privia Health Group, Inc. stockholders’ equity 753,059   737,217 Non-controlling interest 52,845   53,726 Total stockholders’ equity 805,904   790,943 Total liabilities and stockholders’ equity$1,417,892  $1,369,378          (h) Any slight variations in totals are due to rounding.

Privia Health Group, Inc.
Condensed Consolidated Statements of Cash Flows(i)
(unaudited)
(in thousands)
   For the Three Months Ended March 31,  2026   2025 Cash flows from operating activities   Net income$3,710  $6,046 Adjustments to reconcile net income to net cash used in operating activities:   Depreciation 146   228 Amortization of intangibles 3,135   1,673 Stock-based compensation 21,921   17,790 Deferred income taxes, net 2,528   1,713 Changes in asset and liabilities:   Accounts receivable, net (112,774)  (72,548)Prepaid expenses and other current assets (2,408)  (914)Other non-current assets and right-of-use assets 978   275 Accounts payable and accrued expenses (16,249)  (13,850)Provider liability 49,113   35,681 Operating lease liabilities (510)  (155)Other long-term liabilities 945   — Net cash used in operating activities (49,465)  (24,061)Cash from investing activities   Other (26)  — Net cash used in investing activities (26)  — Cash flows from financing activities   Proceeds from exercised stock options 774   2,243 Repurchase of non-controlling interest (11,444)  — Net cash (used in) provided by financing activities (10,670)  2,243 Net decrease in cash and cash equivalents (60,161)  (21,818)Cash and cash equivalents at beginning of period 479,685   491,149 Cash and cash equivalents at end of period$419,524  $469,331     Supplemental disclosure of cash flow information:   Interest paid$62  $— Income tax paid (refunds received)$63  $(313)         (i) Any slight variations in totals are due to rounding.

Additional Financial Information

Revenues disaggregated by source:

 For the Three Months Ended March 31,
(Dollars in thousands)2026
 2025
FFS-patient care$391,133  $311,761 FFS-administrative services 31,403   32,255 Capitated revenue 86,148   70,690 Shared savings 74,962   47,912 Care management fees (PMPM) 17,865   15,201 Other revenue 2,336   2,278 Total Revenue$603,847  $480,097          The Company’s liabilities for unpaid medical claims under at-risk capitation arrangements:

  March 31,(Dollars in thousands)  2026   2025 Balance, beginning of period $78,989  $66,355 Incurred health care costs:    Current year  81,143   70,565 Prior years  435   (954)Total claims incurred $81,578  $69,611 Claims paid:    Current year  (2,088)  (10,273)Prior year  (53,239)  (39,332)Total claims paid $(55,327) $(49,605)Balance, end of period $105,240  $86,361           Key Metrics and Non-GAAP Financial Measures

Privia Health reviews a number of operating and financial metrics, including the following key metrics and non-GAAP financial measures, to evaluate the Company’s business, measure performance, identify trends affecting the Company’s business, formulate business plans, and make strategic decisions.

Key Metrics(j)

  For the Three Months Ended March 31,
(unaudited; $ in millions) 2026
 2025
       Implemented Providers (as of end of period) (1)  5,535   4,871 Attributed Lives (as of end of period) (2)  1,606,000   1,270,000 Practice Collections (3) $914.8  $798.6        (1) Implemented Providers is defined as the total of all service professionals at the end of a given period who are credentialed and bill for medical services in both Owned and Non-Owned Medical Groups during that period.(2) Attributed Lives are defined as any patient that a payer deems attributed to Privia to deliver care as part of a value-based care arrangement through a provider of primary care or specialty services as of the end of a particular period.(3) Practice Collections are defined as the total collections from all practices in all markets and all sources of reimbursement that the Company receives for delivering care and providing Privia Health’s platform and associated services. Practice Collections differ from revenue by including collections from Non-Owned Medical Groups.(j) Any slight variations in totals are due to rounding.   Non-GAAP Financial Measures (4)(k)

  For the Three Months Ended March 31,(unaudited; $ in thousands)  2026   2025      Care Margin $128,730  $105,288 Platform Contribution $67,033  $51,733 Platform Contribution Margin  52.1%  49.1%Adjusted EBITDA $36,691  $26,915 Adjusted EBITDA Margin  28.5%  25.6%     (4) In addition to results reported in accordance with GAAP, Privia Health discloses Care Margin, Platform Contribution, Platform Contribution margin, Adjusted EBITDA and Adjusted EBITDA Margin, which are non-GAAP financial measures. Each are defined as follows: Care Margin is Gross Profit excluding amortization of intangible assets.Platform Contribution is Gross Profit, excluding amortization of intangible assets, less Cost of platform and excluding stock-based compensation expense included in Cost of platform.Platform Contribution margin is Platform Contribution divided by Care Margin.Adjusted EBITDA is net income before interest income, net, provision for income taxes, net income attributable to non-controlling interests, depreciation and amortization, stock-based compensation, employer taxes on equity vesting/exercises, severance charges, contingent and deferred consideration, and other non-recurring expenses.Adjusted EBITDA Margin is Adjusted EBITDA divided by Care Margin. (k) Any slight variations in totals are due to rounding.  Reconciliation of Gross Profit to Care Margin(l)

  For the Three Months Ended March 31,(unaudited; $ in thousands)  2026   2025 Revenue $603,847  $480,097 Provider expense  (475,117)  (374,809)Amortization of intangible assets  (3,135)  (1,673)Gross Profit $125,595  $103,615 Amortization of intangibles assets  3,135   1,673 Care Margin $128,730  $105,288 (l)Any slight variations in totals are due to rounding.  Reconciliation of Gross Profit to Platform Contribution(m)

  For the Three Months Ended March 31,(unaudited; $ in thousands)  2026   2025 Revenue $603,847  $480,097 Provider expense  (475,117)  (374,809)Amortization of intangibles assets  (3,135)  (1,673)Gross Profit $125,595  $103,615 Amortization of intangibles assets  3,135   1,673 Cost of platform  (68,420)  (59,526)Stock-based compensation(5)  6,723   5,971 Platform Contribution $67,033  $51,733 (m) Any slight variations in totals are due to rounding.(5) Amount represents stock-based compensation expense included in Cost of platform.  Reconciliation of Net Income to Adjusted EBITDA(n)

  For the Three Months Ended March 31,(unaudited; $ in thousands)  2026   2025 Net income $3,064  $4,220 Net income attributable to non-controlling interests  646   1,826 Provision for income taxes  5,600   2,103 Interest income, net  (1,888)  (2,931)Depreciation and amortization  3,281   1,901 Stock-based compensation  21,921   17,790 Other expenses(6)  4,067   2,006 Adjusted EBITDA $36,691  $26,915      (n) Any slight variations in totals are due to rounding.(6) Other expenses include employer taxes on equity vesting/exercises, severance, contingent and deferred consideration, and other non-recurring expenses.  Reconciliation of Net Income to Adjusted Net Income and Adjusted Net Income Per Share(o)

 For the Three Months Ended March 31,(unaudited; $ in thousands) 2026   2025 (9) Net income$3,064  $4,220 Stock-based compensation 21,921   17,790 Intangible amortization expense 3,135   1,673 Other expenses(7) 4,067   2,006 Tax effect of adjustments(8) (7,863)  (5,796)Adjusted net income$24,324  $19,893 Adjusted net income per share attributable to Privia Health Group, Inc. stockholders – basic$0.20  $0.16 Adjusted net income per share attributable to Privia Health Group, Inc. stockholders – diluted$0.19  $0.16 Weighted average common shares outstanding – basic 124,152,526   120,623,670 Weighted average common shares outstanding – diluted 130,878,939   127,752,527 (o) Any slight variations in totals due to rounding.(7) Other expenses include employer taxes on equity vesting/exercises, severance, contingent and deferred consideration, and other non-recurring expenses.(8) The Company uses a statutory blended tax rate of 27% on the adjustments between Net Income and Adjusted Net Income.(9) Updated to conform with current year presentation. 

Although the revenue and EPS for Privia Health (PRVA) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

MarketBeat Instant News Alerts Trending News All MarketBeat Instant News Alerts Sort By

Time Frame

Alert Type

Keywords

Page 1 of 324

Get 30 Days of MarketBeat All Access for Free

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools.

Start Your 30-Day Trial

Sign in to your free account to enjoy these benefits

In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer.

ARLINGTON, Va., May 27, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA), a national physician enablement company, announced it has signed a definitive agreement to enter the state of New Jersey in partnership with Neurology Group of Bergen County (NGBC), a practice with 25 adult and pediatric clinicians.

NGBC will serve as the anchor practice for Privia Medical Group—New Jersey and is expected to be implemented on the Privia Platform by year-end 2026. Privia Health will provide an alternative for community clinicians in New Jersey to care for patients across all reimbursement models, leveraging a breadth of interoperable solutions and population health expertise to enable care insights and collaboration.

“We are thrilled to welcome Neurology Group of Bergen County into our network. NGBC is one of the largest and most respected independent neurology practices in the Northeast, with an exceptional team and a decades-long track record of delivering outstanding patient outcomes," said Jason Ross, EVP Medical Groups of Privia Health. “We look forward to supporting the NGBC team as they continue to serve the Bergen County community.”

“Partnering with Privia was the right next step for our practice and, most importantly, for our patients. They share our commitment to clinical excellence and the kind of personalized, compassionate care we’ve built over the past 50 years,” said NGBC physician John T. Nasr, M.D. “This partnership gives us the resources and support to expand access to high-quality neurological care across our community, while preserving the independent culture that has defined NGBC.”

About Privia Health

Privia Health is one of the largest physician enablement companies in the United States with a presence in 25 states and the District of Columbia. Privia builds scaled provider networks with primary-care centric medical groups, risk-bearing entities, a physician-led governance structure, and the Privia Platform comprising an extensive suite of technology and service solutions. Privia collaborates with medical groups, health plans and health systems to optimize 1,300+ physician practices, improve the patient experience for 5.9+ million patients, and reward 5,500+ physicians and advanced practitioners for delivering high-value care.

Privia’s mission is to transform healthcare delivery to achieve better outcomes, lower costs, and improve the health of communities and the well-being of providers. For more information, visit priviahealth.com and connect with us on LinkedIn.

Safe Harbor Statement

This release may contain “forward-looking statements” within the meaning of the safe-harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks, uncertainties (some of which are beyond the Company’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those described in the Company’s filings with the Securities and Exchange Commission, including those set forth under “Risk Factors” therein. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Forward-looking statements speak only as of the date made. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Contact:

Robert Borchert
SVP, Investor & Corporate Communications
[email protected]
817.783.4841

Fort Lauderdale, May 28, 2026 (GLOBE NEWSWIRE) -- Cross Keys Capital, LLC, a leading independent investment banking firm providing M&A advisory services to physician group practices and healthcare services companies,is  pleased to announce it acted as the exclusive financial advisor to the Neurology Group of Bergen County (“NGBC”) in its partnership with Privia Health.

Founded in 1973, the Neurology Group of Bergen County is one of the region's most respected independent neurology practices, serving the communities of Bergen County, New Jersey. NGBC comprises 25 adult and pediatric clinicians operating at one central Ridgewood, NJ location. The practice provides comprehensive, state-of-the-art diagnostic testing and treatment across the full spectrum of neurological conditions, including epilepsy, multiple sclerosis, stroke, headache disorders, movement disorders, neuropathy, and pediatric neurology.

“Partnering with Privia was the right next step for our practice and, most importantly, for our patients. They share our commitment to clinical excellence and the kind of personalized, compassionate care we've built over the past 50 years,” said NGBC physicians Hugo Lijtmaer, M.D., Kenneth Citak, M.D. and John T. Nasr, M.D. “This partnership gives us the resources and support to expand access to high-quality neurological care across our community, while preserving the independent culture that has defined NGBC. We are grateful to the Cross Keys team for their expert guidance throughout this process. They made sure every aspect of the transaction reflected our values and long-term vision.”

The Cross Keys Capital deal team consisted of Bill Britton, Chris Gammill, and Victor Arocho. NGBC was represented by Brach Eichler’s legal team consisting of Joseph M. Gorrell, Caroline J. Patterson and Erika Marshall. Terms of the transaction were not disclosed.

About Privia Health

Privia Health is one of the largest physician enablement companies in the United States with a presence in 25 states and the District of Columbia. Privia builds scaled provider networks with primary-care centric medical groups, risk-bearing entities, a physician-led governance structure, and the Privia Platform comprising an extensive suite of technology and service solutions. Privia collaborates with medical groups, health plans and health systems to optimize 1,300+ physician practices, improve the patient experience for 5.9+ million patients, and reward 5,500+ physicians and advanced practitioners for delivering high-value care.

Privia’s mission is to transform healthcare delivery to achieve better outcomes, lower costs, and improve the health of communities and the well-being of providers. For more information, visit priviahealth.com.

About Cross Keys Capital

Cross Keys Capital is a leading middle-market investment bank providing a full range of investment banking merger and acquisition advisory services to a variety of businesses nationally.

Cross Keys Capital’s healthcare services team is nationally recognized as a leader in providing merger and acquisition advisory services to independent physician group practices and healthcare services companies. To date, the firm’s healthcare practice has completed the sale or merger of over 200 transactions including independent physician group practices, healthcare services providers, and healthcare technology companies. For more information on Cross Keys Capital or to discuss a potential partnership or sale, please contact Bill Britton, Managing Director, at 954-410-1936 or [email protected]. Visit us online at www.ckcap.com.

On June 04, 2026, Privia Health Group Inc PRVA shares rose 3.4% to a current price of $21.37. Over the past 52 weeks, the stock has traded between $18.77 and $26.51, indicating significant volatility. The recent price increase provides a slight buffer against an overall year-to-date decline of 9.9%.

GF Value™ verdict: PRVA is currently priced at $21.37, which is 21.4% below its GF Value™ estimate of $27.19.GF Score™ of 87/100 indicates a strong overall rating, suggesting good long-term investment potential.Insider activity has shown that insiders sold $8.2 million in stock over the last three months, suggesting caution among company executives. Is PRVA Overvalued or Undervalued? Based on the current price of $21.37 compared to its GF Value™ estimate of $27.19, Privia Health Group Inc appears to be undervalued by approximately 21.4%. This margin of safety signifies that there may be opportunities for growth if the stock price aligns more closely with its intrinsic value. The GF Valuation label categorizes the stock as "Modestly Undervalued," indicating that while there is room for appreciation, potential investors should still exercise caution due to market conditions and inherent risks in the healthcare sector.

GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates. Given that the stock is trading below its estimated fair value, it presents an attractive opportunity, but investors must monitor market trends and company performance closely before making decisions.

How Does PRVA's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 133.6x 158.4x Forward P/E 84.8x N/A Currently, Privia Health Group Inc's P/E ratio is 133.6x, which is 16% below its 5-year median P/E of 158.4x. This indicates that the stock is trading below its historical valuation metrics. The P/E analysis aligns with the GF Value™ verdict of being undervalued, suggesting that the stock has potential for price appreciation as it approaches its historical averages.

What Does PRVA's GF Score™ Tell Us? Metric Rating GF Score™ 87/100 Financial Strength 8/10 Profitability 6/10 Growth 9/10 Valuation 8/10 Momentum 7/10 The GF Score™ of 87/100 indicates a strong overall rating for Privia Health Group Inc, driven primarily by its impressive growth rank of 9/10 and solid financial strength at 8/10. However, profitability ranks lower at 6/10, suggesting that while the company's financial health is robust, there may be challenges in generating consistent profits. Overall, the strong GF Score™ reflects a favorable outlook, but the weaker profitability ranking highlights an area that needs attention.

What Are Insiders Doing with PRVA Stock? In the last three months, insiders at Privia Health Group Inc have sold a total of $8.2 million in stock, with no insider buying reported during this period. This trend of selling by insiders could signal a lack of confidence in the near-term performance of the company or a strategic move to realize gains. Generally, heavy insider selling without corresponding buying can be interpreted as a cautious signal for potential investors.

What This Means for Investors Based on the GF Value™ analysis, Privia Health Group Inc PRVA is currently undervalued. The stock's price of $21.37 is significantly below its estimated fair value of $27.19, indicating potential for price appreciation. However, investors should remain vigilant regarding insider selling trends and overall market conditions that may affect future performance.

For the complete analysis, visit the Privia Health Group Inc PRVA stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.

Frequently Asked Questions What is PRVA's GF Score™?

PRVA has a GF Score™ of 87/100, indicating a strong overall rating that suggests good long-term investment potential.

Is PRVA overvalued or undervalued?

PRVA is currently undervalued, with a GF Value™ estimate of $27.19 compared to its market price of $21.37.

What is PRVA's P/E ratio?

PRVA's P/E ratio is 133.6x, which is 16% below its 5-year median P/E of 158.4x, indicating that the stock is trading below its historical valuation.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].